Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas

Blood (2024) 144 (Supplement 1): 856.

https://doi.org/10.1182/blood-2024-199257

Published: 2024

Journal Articles

Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Blood (2024) 144 (Supplement 1): 1583.

https://doi.org/10.1182/blood-2024-202943

Published: 2024

Journal Articles

Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma - a Retrospective Clinical Study

Kudret Kama, Alexandra Kutilina, Julia Wendler, Hannes Treiber, Stefan Trefz, Jürgen Finke, Gerald Wulf, Lisa Isbell, Aslihan Arslan, Antje Jensch, Elisabeth Schorb, Gerald Illerhaus

Blood (2024) 144 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2024-208511

Published: 2024

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Blood (2022) 140 (Supplement 1): 1773–1774.

https://doi.org/10.1182/blood-2022-162157

Published: 2022

Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J.M. Ferreri, Kate Cwynarski, Pamela McKay

Blood (2022) 139 (16): 2499–2511.

https://doi.org/10.1182/blood.2021014506

Published: 2022

Includes: Supplemental data

Journal Articles

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Blood (2021) 138 (Supplement 1): 6.

https://doi.org/10.1182/blood-2021-149644

Published: 2021

Journal Articles

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Blood (2021) 138 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2021-147822

Published: 2021

Journal Articles

Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Matthew R Wilson, Toby A. Eyre, Amy A Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolas Martinex-Calle, Gavin Preston, Matthew J Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L Lewis, Teresa Calimeri, Eric Durot, Loic Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Tim Ebsworth, Johnathon Elliot, Anna Santarsiere, Laure Ricard, Nimish Shah, Qin Liu, Adam Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish W Scott, Anna Guidetti, Brett R Barlow, Jeffrey Smith, Tarec Christoffer El-Galaly, Chan Yoon Cheah, Andres JM Ferreri, Fiona Miall, Christopher P Fox, Kate Cwynarski, Pamela McKay

Blood (2021) 138 (Supplement 1): 452.

https://doi.org/10.1182/blood-2021-144820

Published: 2021

Journal Articles

Hyper- N -glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Blood (2018) 132 (26): 2744–2753.

https://doi.org/10.1182/blood-2018-03-836932

Published: 2018

Includes: Supplemental data

Journal Articles

Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis

Hans-Guido Holl, MD, Elisabeth Schorb, MD, Jürgen Finke, MD, Nikolaos Vassiliadis, Benjamin Kasenda, MDPhD, Gerald Illerhaus, MD

Blood (2018) 132 (Supplement 1): 1705.

https://doi.org/10.1182/blood-2018-99-117329

Published: 2018

Journal Articles

Novel agents for primary central nervous system lymphoma: evidence and perspectives

Gerald Illerhaus, Elisabeth Schorb, Benjamin Kasenda

Blood (2018) 132 (7): 681–688.

https://doi.org/10.1182/blood-2018-01-791558

Published: 2018

Journal Articles

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Elisabeth Schorb, MD, Chris P Fox, Benjamin Kasenda, MDPhD, Teresa Calimeri, MDPhD, Kim Linton, MBChB PhD, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Slavisa Ninkovic, MBBS FRACP FRCPA, Deborah Yallop, MBBS FRCP FRCPath PhD, Hans-Guido Holl, MD, Alberto Fabbri, MD, Thomas E C Cummin, MRCP MBBCh BSc, Gerald Illerhaus, MD, Kate Cwynarski, PhDMD, Andrés J M Ferreri, MD

Blood (2017) 130 (Supplement 1): 376.

https://doi.org/10.1182/blood.V130.Suppl_1.376.376

Published: 2017

Journal Articles

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

Benjamin Kasenda, MD PhD, Gabriele Ihorst, PhD, Heidi Fricker, Elke Valk, PhD, Elisabeth Schorb, MD, Kristina Fritsch, MD, Jürgen Finke, Gerald Illerhaus, MD

Blood (2016) 128 (22): 5385.

https://doi.org/10.1182/blood.V128.22.5385.5385

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group

Gerald Illerhaus, MD, Kristina Fritsch, MD, Ingo Schmidt-Wolf, MD, Roland Schroers, MD, Gerlinde Egerer, MD, Agnieszka Korfel, MD, Tobias Birnbaum, MD, Monika Lamprecht, MD, Nikolas von Bubnoff, Hans-Heinrich Wolf, MD, Stephan Stilgenbauer, MD, Martin Trepel, MD PhD, Robert Möhle, MD, Claudia Hader, MD, Gabriele Ihorst, Heidi Fricker, Benjamin Kasenda, MD, Elisabeth Schorb, MD, Jürgen Finke, MD

Blood (2014) 124 (21): 2527.

https://doi.org/10.1182/blood.V124.21.2527.2527

Published: 2014

Journal Articles

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

Blood (2012) 120 (21): 302.

https://doi.org/10.1182/blood.V120.21.302.302

Published: 2012

Journal Articles

FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma

Benjamin Kasenda, MD, Vanessa Haug, Elisabeth Schorb, MD, Kristina Fritsch, MD, Wolfgang Weber, MD, Jürgen Finke, MD, Gerald Illerhaus, MD, Philipp T Meyer, MD

Blood (2011) 118 (21): 2687.

https://doi.org/10.1182/blood.V118.21.2687.2687

Published: 2011

Journal Articles

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Elisabeth Schorb, MD, Benjamin Kasenda, MD, Johannes Atta, Nikolas von Bubnoff, MD, Thomas Elter, MD, Georg Hess, Stefan W. Krause, MD, Anke Morgner, Kaun Stephan, Kristina Fritsch, MD, Jürgen Finke, MD, Gerald Illerhaus

Blood (2011) 118 (21): 3089.

https://doi.org/10.1182/blood.V118.21.3089.3089

Published: 2011

NARROW

Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas

Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Combining Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in Relapsed or Refractory Central Nervous System Lymphoma - a Retrospective Clinical Study

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients - a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Profiling of Circulating Tumor DNA for Noninvasive Disease Detection, Risk Stratification, and MRD Monitoring in Patients with CNS Lymphoma

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients

Hyper- N -glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL - a Multicentre Retrospective Analysis

Novel agents for primary central nervous system lymphoma: evidence and perspectives

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials

High Dose-Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation for Patients with Refractory or Recurrent Primary Central Nervous System Lymphoma –Results of a Multicenter Study By the Germany Collaborative PCNSL Study Group

Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg

FDG-PET Is An Independent Predictor for Survival in Primary Central Nervous System Lymphoma

Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantaion - a Multicenter Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only